Electrical properties of prostatic tissues: II. Spectral admittivity properties.
OBJECTIVE
The electrical properties of prostate tissues gauged at discrete frequencies provide sufficient contrast to discriminate malignant from benign prostatic tissues. The frequency dependence of these properties is also a function of tissue morphology. We evaluated the potential of this spectral dependence to provide additional diagnostic information for prostate cancer detection.


METHODS
Electrical conductivity and permittivity were recorded from 50 ex vivo prostates at 31 logarithmically spaced frequencies of 100 Hz to 100 kHz. We used a well established, 4 parameter (sigma(infinity), Delta sigma, f(c) and alpha) model to describe individual spectra with each model parameter influenced by tissue morphology. We evaluated these parameters in terms of discriminatory power using ROC curves.


RESULTS
Of the 4 spectral parameters sigma(infinity) and f(c) were significantly greater in cancer than in benign tissues and Delta sigma was significantly more negative in cancer than in benign tissues (each p <0.0001). f(c) provided the maximum discriminating power with an ROC AUC of 0.821 and 81.5% specificity at 70% sensitivity. Also, sigma(infinity) and Delta sigma provided high levels of discrimination with an AUC of 0.770 and 0.782, respectively.


CONCLUSIONS
Spectral electrical admittivity properties provide sufficient levels of ex vivo cancer discrimination that may potentially enhance disease localization when prostate cancer is suspected. The development of novel technologies gauging these properties in vivo has the potential to provide new tissue characterizing tools for prostate cancer detection and identification.
Halter
Ryan J
RJ
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire 03755, USA. ryan.halter@dartmouth.edu
Schned
Alan
A
Heaney
John
J
Hartov
Alex
A
Paulsen
Keith D
KD
D000230:Adenocarcinoma / Q000175:diagnosis / Q000503:physiopathology*; D003937:Diagnosis, Differential; D017097:Electric Impedance; D055724:Electrophysiological Phenomena; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D011467:Prostate / Q000502:physiology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000503:physiopathology*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000503:physiopathology*
Prostate. 1999 May 15;39(3):213-8
10334111
J Urol. 2009 Oct;182(4):1600-7
19683745
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1823-32
17009978
JAMA. 2005 Jul 6;294(1):66-70
15998892
BJU Int. 2006 Feb;97(2):222-3
16430616
Ann N Y Acad Sci. 1999 Apr 20;873:30-41
10372147
Phys Med Biol. 1996 Nov;41(11):2271-93
8938026
Physiol Meas. 2008 Jun;29(6):S111-23
18544804
Physiol Meas. 2009 Jun;30(6):S1-18
19491445
Phys Med Biol. 2002 Jul 7;47(13):2189-202
12164581
Eur Urol. 2009 Feb;55(2):376-83
18359147
J Urol. 2008 Apr;179(4):1580-6
18295258
IEEE Trans Biomed Eng. 2007 Jul;54(7):1321-7
17605363
Lancet. 2000 Mar 11;355(9207):892-5
10752706